Brasília – The Ministry of Health signed two new technology transfer agreements under the Productive Development Partnerships (PDPs): one for a Respiratory Syncytial Virus (RSV) vaccine with Instituto Butantan and Pfizer, and another for the biologic natalizumab, used in multiple sclerosis, with Sandoz and Butantan.

The RSV vaccine’s first 1.8 million doses are expected by year-end, and SUS distribution will begin in late November, potentially preventing around 28,000 hospitalizations annually and benefiting approximately 2 million babies. The natalizumab agreement aims to foster competition and reduce reliance on a single supplier.

In addition, the Ministry’s Science, Technology, Innovation and CEIS Secretariat released preliminary results from the latest PDP cycle: 12 projects approved and 36 rejected. Among the approved are nine cancer treatments and three new vaccines—including rabies, varicella, and the mRNA COVID-19 vaccine mRNS-1273 developed by Moderna and produced by Butantan.

Source: Futuro da Saúde

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com